Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 57


Antibody Fab-Fc properties outperform titer in predictive models of SIV vaccine-induced protection.

Pittala S, Bagley K, Schwartz JA, Brown EP, Weiner JA, Prado IJ, Zhang W, Xu R, Ota-Setlik A, Pal R, Shen X, Beck C, Ferrari G, Lewis GK, LaBranche CC, Montefiori DC, Tomaras GD, Alter G, Roederer M, Fouts TR, Ackerman ME, Bailey-Kellogg C.

Mol Syst Biol. 2019 May 2;15(5):e8747. doi: 10.15252/msb.20188747.


Mucosal vaccine efficacy against intrarectal SHIV is independent of anti-Env antibody response.

Sui Y, Lewis GK, Wang Y, Berckmueller K, Frey B, Dzutsev A, Vargas-Inchaustegui D, Mohanram V, Musich T, Shen X, DeVico A, Fouts T, Venzon D, Kirk J, Waters RC, Talton J, Klinman D, Clements J, Tomaras GD, Franchini G, Robert-Guroff M, Trinchieri G, Gallo RC, Berzofsky JA.

J Clin Invest. 2019 Mar 1;129(3):1314-1328. doi: 10.1172/JCI122110. Epub 2019 Feb 18.


Estimating One-Year Risk of Incident Chronic Kidney Disease: Retrospective Development and Validation Study Using Electronic Medical Record Data From the State of Maine.

Hao S, Fu T, Wu Q, Jin B, Zhu C, Hu Z, Guo Y, Zhang Y, Yu Y, Fouts T, Ng P, Culver DS, Alfreds ST, Stearns F, Sylvester KG, Widen E, McElhinney DB, Ling XB.

JMIR Med Inform. 2017 Jul 26;5(3):e21. doi: 10.2196/medinform.7954.


An Interleukin 12 Adjuvanted Herpes Simplex Virus 2 DNA Vaccine Is More Protective Than a Glycoprotein D Subunit Vaccine in a High-Dose Murine Challenge Model.

Bagley KC, Schwartz JA, Andersen H, Eldridge JH, Xu R, Ota-Setlik A, Geltz JJ, Halford WP, Fouts TR.

Viral Immunol. 2017 Apr;30(3):178-195. doi: 10.1089/vim.2016.0136. Epub 2017 Jan 13.


Adsorption of a synthetic TLR7/8 ligand to aluminum oxyhydroxide for enhanced vaccine adjuvant activity: A formulation approach.

Fox CB, Orr MT, Van Hoeven N, Parker SC, Mikasa TJ, Phan T, Beebe EA, Nana GI, Joshi SW, Tomai MA, Elvecrog J, Fouts TR, Reed SG.

J Control Release. 2016 Dec 28;244(Pt A):98-107. doi: 10.1016/j.jconrel.2016.11.011. Epub 2016 Nov 12.


Retinaldehyde dehydrogenase 2 as a molecular adjuvant for enhancement of mucosal immunity during DNA vaccination.

Holechek SA, McAfee MS, Nieves LM, Guzman VP, Manhas K, Fouts T, Bagley K, Blattman JN.

Vaccine. 2016 Nov 4;34(46):5629-5635. doi: 10.1016/j.vaccine.2016.09.013. Epub 2016 Sep 23.


Boosting of ALVAC-SIV Vaccine-Primed Macaques with the CD4-SIVgp120 Fusion Protein Elicits Antibodies to V2 Associated with a Decreased Risk of SIVmac251 Acquisition.

Gordon SN, Liyanage NP, Doster MN, Vaccari M, Vargas-Inchaustegui DA, Pegu P, Schifanella L, Shen X, Tomaras GD, Rao M, Billings EA, Schwartz J, Prado I, Bobb K, Zhang W, Montefiori DC, Foulds KE, Ferrari G, Robert-Guroff M, Roederer M, Phan TB, Forthal DN, Stablein DM, Phogat S, Venzon DJ, Fouts T, Franchini G.

J Immunol. 2016 Oct 1;197(7):2726-37. doi: 10.4049/jimmunol.1600674. Epub 2016 Sep 2.


An HIV gp120-CD4 Immunogen Does Not Elicit Autoimmune Antibody Responses in Cynomolgus Macaques.

Schwartz JA, Prado I, Misamore J, Weiss D, Francis J, Pal R, Huaman M, Cristillo A, Lewis GK, Gallo RC, DeVico AL, Fouts TR.

Clin Vaccine Immunol. 2016 Jul 5;23(7):618-27. doi: 10.1128/CVI.00115-16. Print 2016 Jul.


Paring Down HIV Env: Design and Crystal Structure of a Stabilized Inner Domain of HIV-1 gp120 Displaying a Major ADCC Target of the A32 Region.

Tolbert WD, Gohain N, Veillette M, Chapleau JP, Orlandi C, Visciano ML, Ebadi M, DeVico AL, Fouts TR, Finzi A, Lewis GK, Pazgier M.

Structure. 2016 May 3;24(5):697-709. doi: 10.1016/j.str.2016.03.005. Epub 2016 Mar 31.


Expression of Human Immunodeficiency Virus Type 1 Neutralizing Antibody Fragments Using Human Vaginal Lactobacillus.

Marcobal A, Liu X, Zhang W, Dimitrov AS, Jia L, Lee PP, Fouts TR, Parks TP, Lagenaur LA.

AIDS Res Hum Retroviruses. 2016 Oct/Nov;32(10-11):964-971. Epub 2016 Apr 13.


Synergistic Inhibition of R5 HIV-1 by the Fusion Protein (FLSC) IgG1 Fc and Maraviroc in Primary Cells: Implications for Prevention and Treatment.

Latinovic OS, Zhang J, Tagaya Y, DeVico AL, Fouts TR, Schneider K, Lakowicz JR, Heredia A, Redfield RR.

Curr HIV Res. 2016;14(1):24-36.


The catalytic A1 domains of cholera toxin and heat-labile enterotoxin are potent DNA adjuvants that evoke mixed Th1/Th17 cellular immune responses.

Bagley K, Xu R, Ota-Setlik A, Egan M, Schwartz J, Fouts T.

Hum Vaccin Immunother. 2015;11(9):2228-40. doi: 10.1080/21645515.2015.1026498.


NF-κB-activating complex engaged in response to EGFR oncogene inhibition drives tumor cell survival and residual disease in lung cancer.

Blakely CM, Pazarentzos E, Olivas V, Asthana S, Yan JJ, Tan I, Hrustanovic G, Chan E, Lin L, Neel DS, Newton W, Bobb KL, Fouts TR, Meshulam J, Gubens MA, Jablons DM, Johnson JR, Bandyopadhyay S, Krogan NJ, Bivona TG.

Cell Rep. 2015 Apr 7;11(1):98-110. doi: 10.1016/j.celrep.2015.03.012. Epub 2015 Apr 2.


Balance of cellular and humoral immunity determines the level of protection by HIV vaccines in rhesus macaque models of HIV infection.

Fouts TR, Bagley K, Prado IJ, Bobb KL, Schwartz JA, Xu R, Zagursky RJ, Egan MA, Eldridge JH, LaBranche CC, Montefiori DC, Le Buanec H, Zagury D, Pal R, Pavlakis GN, Felber BK, Franchini G, Gordon S, Vaccari M, Lewis GK, DeVico AL, Gallo RC.

Proc Natl Acad Sci U S A. 2015 Mar 3;112(9):E992-9. doi: 10.1073/pnas.1423669112. Epub 2015 Feb 13. Erratum in: Proc Natl Acad Sci U S A. 2015 May 5;112(18):E2413.


HIV-1 CD4-induced (CD4i) gp120 epitope vaccines promote B and T-cell responses that contribute to reduced viral loads in rhesus macaques.

Thomas MA, Tuero I, Demberg T, Vargas-Inchaustegui DA, Musich T, Xiao P, Venzon D, LaBranche C, Montefiori DC, DiPasquale J, Reed SG, DeVico A, Fouts T, Lewis GK, Gallo RC, Robert-Guroff M.

Virology. 2014 Dec;471-473:81-92. doi: 10.1016/j.virol.2014.10.001. Epub 2014 Oct 28.


Diverse specificity and effector function among human antibodies to HIV-1 envelope glycoprotein epitopes exposed by CD4 binding.

Guan Y, Pazgier M, Sajadi MM, Kamin-Lewis R, Al-Darmarki S, Flinko R, Lovo E, Wu X, Robinson JE, Seaman MS, Fouts TR, Gallo RC, DeVico AL, Lewis GK.

Proc Natl Acad Sci U S A. 2013 Jan 2;110(1):E69-78. doi: 10.1073/pnas.1217609110. Epub 2012 Dec 13.


Identification and characterization of an immunogenic hybrid epitope formed by both HIV gp120 and human CD4 proteins.

Lewis GK, Fouts TR, Ibrahim S, Taylor BM, Salkar R, Guan Y, Kamin-Lewis R, Robinson JE, Devico AL.

J Virol. 2011 Dec;85(24):13097-104. doi: 10.1128/JVI.05072-11. Epub 2011 Oct 12. Erratum in: J Virol. 2012 May;86(9):5410. Robinson, James E [added].


Adjuvant activity of the catalytic A1 domain of cholera toxin for retroviral antigens delivered by GeneGun.

Bagley KC, Lewis GK, Fouts TR.

Clin Vaccine Immunol. 2011 Jun;18(6):922-30. doi: 10.1128/CVI.05019-11. Epub 2011 Apr 20.


Development and validation of a decision-making algorithm to guide the use of plerixafor for autologous hematopoietic stem cell mobilization.

Costa LJ, Alexander ET, Hogan KR, Schaub C, Fouts TV, Stuart RK.

Bone Marrow Transplant. 2011 Jan;46(1):64-9. doi: 10.1038/bmt.2010.78. Epub 2010 Apr 12.


Potent and broad neutralizing activity of a single chain antibody fragment against cell-free and cell-associated HIV-1.

Zhang MY, Borges AR, Ptak RG, Wang Y, Dimitrov AS, Alam SM, Wieczorek L, Bouma P, Fouts T, Jiang S, Polonis VR, Haynes BF, Quinnan GV, Montefiori DC, Dimitrov DS.

MAbs. 2010 May-Jun;2(3):266-74. Epub 2010 May 5.


Neutralization of HIV by antibodies.

Prado I, Fouts TR, Dimitrov AS.

Methods Mol Biol. 2009;525:517-31, xiv. doi: 10.1007/978-1-59745-554-1_28.


Discordant memory B cell and circulating anti-Env antibody responses in HIV-1 infection.

Guan Y, Sajadi MM, Kamin-Lewis R, Fouts TR, Dimitrov A, Zhang Z, Redfield RR, DeVico AL, Gallo RC, Lewis GK.

Proc Natl Acad Sci U S A. 2009 Mar 10;106(10):3952-7. doi: 10.1073/pnas.0813392106. Epub 2009 Feb 18.


Antibodies to CD4-induced sites in HIV gp120 correlate with the control of SHIV challenge in macaques vaccinated with subunit immunogens.

DeVico A, Fouts T, Lewis GK, Gallo RC, Godfrey K, Charurat M, Harris I, Galmin L, Pal R.

Proc Natl Acad Sci U S A. 2007 Oct 30;104(44):17477-82. Epub 2007 Oct 23.


Structure and function of the HIV envelope glycoprotein as entry mediator, vaccine immunogen, and target for inhibitors.

Prabakaran P, Dimitrov AS, Fouts TR, Dimitrov DS.

Adv Pharmacol. 2007;55:33-97. Review. No abstract available.


Cross-reactive HIV-1 neutralizing monoclonal antibodies selected by screening of an immune human phage library against an envelope glycoprotein (gp140) isolated from a patient (R2) with broadly HIV-1 neutralizing antibodies.

Choudhry V, Zhang MY, Sidorov IA, Louis JM, Harris I, Dimitrov AS, Bouma P, Cham F, Choudhary A, Rybak SM, Fouts T, Montefiori DC, Broder CC, Quinnan GV Jr, Dimitrov DS.

Virology. 2007 Jun 20;363(1):79-90. Epub 2007 Feb 15. Erratum in: Virology. 2007 Nov 25;368(2):431.


Increased efficacy of HIV-1 neutralization by antibodies at low CCR5 surface concentration.

Choudhry V, Zhang MY, Harris I, Sidorov IA, Vu B, Dimitrov AS, Fouts T, Dimitrov DS.

Biochem Biophys Res Commun. 2006 Sep 29;348(3):1107-15. Epub 2006 Aug 4.


An immunoglobulin fusion protein based on the gp120-CD4 receptor complex potently inhibits human immunodeficiency virus type 1 in vitro.

Vu JR, Fouts T, Bobb K, Burns J, McDermott B, Israel DI, Godfrey K, DeVico A.

AIDS Res Hum Retroviruses. 2006 Jun;22(6):477-90.


Antibody-based inhibitors of HIV infection.

Choudhry V, Zhang MY, Dimitrova D, Prabakaran P, Dimitrov AS, Fouts TR, Dimitrov DS.

Expert Opin Biol Ther. 2006 May;6(5):523-31. Review.


Induction of neutralizing antibodies against human immunodeficiency virus type 1 primary isolates by Gag-Env pseudovirion immunization.

Hammonds J, Chen X, Fouts T, DeVico A, Montefiori D, Spearman P.

J Virol. 2005 Dec;79(23):14804-14.


Gp120 stability on HIV-1 virions and Gag-Env pseudovirions is enhanced by an uncleaved Gag core.

Hammonds J, Chen X, Ding L, Fouts T, De Vico A, zur Megede J, Barnett S, Spearman P.

Virology. 2003 Sep 30;314(2):636-49.


Progress toward the development of a bacterial vaccine vector that induces high-titer long-lived broadly neutralizing antibodies against HIV-1.

Fouts TR, DeVico AL, Onyabe DY, Shata MT, Bagley KC, Lewis GK, Hone DM.

FEMS Immunol Med Microbiol. 2003 Jul 15;37(2-3):129-34. Review.


Development of vaccination strategies that elicit broadly neutralizing antibodies against human immunodeficiency virus type 1 in both the mucosal and systemic immune compartments.

Hone DM, DeVico AL, Fouts TR, Onyabe DY, Agwale SM, Wambebe CO, Blattner WA, Gallo RC, Lewis GK.

J Hum Virol. 2002 Jan-Feb;5(1):17-23. Review.


Crosslinked HIV-1 envelope-CD4 receptor complexes elicit broadly cross-reactive neutralizing antibodies in rhesus macaques.

Fouts T, Godfrey K, Bobb K, Montefiori D, Hanson CV, Kalyanaraman VS, DeVico A, Pal R.

Proc Natl Acad Sci U S A. 2002 Sep 3;99(18):11842-7. Epub 2002 Aug 21.


Conserved structures exposed in HIV-1 envelope glycoproteins stabilized by flexible linkers as potent entry inhibitors and potential immunogens.

Chow YH, Wei OL, Phogat S, Sidorov IA, Fouts TR, Broder CC, Dimitrov DS.

Biochemistry. 2002 Jun 4;41(22):7176-82.


Development of an oral prime-boost strategy to elicit broadly neutralizing antibodies against HIV-1.

Devico AL, Fouts TR, Shata MT, Kamin-Lewis R, Lewis GK, Hone DM.

Vaccine. 2002 May 6;20(15):1968-74. Review.


An HIV-1 transgenic rat that develops HIV-related pathology and immunologic dysfunction.

Reid W, Sadowska M, Denaro F, Rao S, Foulke J Jr, Hayes N, Jones O, Doodnauth D, Davis H, Sill A, O'Driscoll P, Huso D, Fouts T, Lewis G, Hill M, Kamin-Lewis R, Wei C, Ray P, Gallo RC, Reitz M, Bryant J.

Proc Natl Acad Sci U S A. 2001 Jul 31;98(16):9271-6.


Expression and characterization of a single-chain polypeptide analogue of the human immunodeficiency virus type 1 gp120-CD4 receptor complex.

Fouts TR, Tuskan R, Godfrey K, Reitz M, Hone D, Lewis GK, DeVico AL.

J Virol. 2000 Dec;74(24):11427-36.


Correlation between humoral responses to human immunodeficiency virus type 1 envelope and disease progression in early-stage infection.

Loomis-Price LD, Cox JH, Mascola JR, VanCott TC, Michael NL, Fouts TR, Redfield RR, Robb ML, Wahren B, Sheppard HW, Birx DL.

J Infect Dis. 1998 Nov;178(5):1306-16.


Evidence that antibody-mediated neutralization of human immunodeficiency virus type 1 by sera from infected individuals is independent of coreceptor usage.

Montefiori DC, Collman RG, Fouts TR, Zhou JY, Bilska M, Hoxie JA, Moore JP, Bolognesi DP.

J Virol. 1998 Mar;72(3):1886-93.


An investigation of the high-avidity antibody response to glycoprotein 120 of human immunodeficiency virus type 1.

Binley JM, Arshad H, Fouts TR, Moore JP.

AIDS Res Hum Retroviruses. 1997 Aug 10;13(12):1007-15.


Neutralizing antibodies to human immunodeficiency virus type-1 gp120 induce envelope glycoprotein subunit dissociation.

Poignard P, Fouts T, Naniche D, Moore JP, Sattentau QJ.

J Exp Med. 1996 Feb 1;183(2):473-84.


Optimization of live oral Salmonella-HIV-1 vaccine vectors for the induction of HIV-specific mucosal and systemic immune responses.

Hone DM, Wu S, Powell RJ, Pascual DW, Van Cott J, McGhee J, Fouts TR, Tuskan RG, Lewis GK.

J Biotechnol. 1996 Jan 26;44(1-3):203-7. Review.


Construction and immunogenicity of Salmonella typhimurium vaccine vectors that express HIV-1 gp120.

Fouts TR, Tuskan RG, Chada S, Hone DM, Lewis GK.

Vaccine. 1995 Dec;13(17):1697-705.


Salmonella typhi vaccine strain CVD 908 expressing the circumsporozoite protein of Plasmodium falciparum: strain construction and safety and immunogenicity in humans.

Gonzalez C, Hone D, Noriega FR, Tacket CO, Davis JR, Losonsky G, Nataro JP, Hoffman S, Malik A, Nardin E, Sztein MB, Heppner DG, Fouts TR, Isibasi A, Levine MM, et al.

J Infect Dis. 1994 Apr;169(4):927-31.


Supplemental Content

Support Center